Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab.

Inflamm Bowel Dis · 2023 · PMC10393210 · PMID 36748574

Europe PMC DOI

hedged sentence

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

did not reach statistical significanceP = .14not close (p > 0.1)

While inflammation- and hypoxia-associated parameters differed markedly between healthy control subjects and the IBD group, a 36% difference between median hepcidin levels did not reach statistical significance (21.19 ng/mL vs 13.52 ng/mL in control subjects and patients with IBD, respectively; P = .14).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.